Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

NAActive, not recruitingINTERVENTIONAL
Enrollment

504

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Brain MetastasisOligoprogression
Interventions
RADIATION

Hypofractionated SRT (stereotactic radiotherapy)

3\*10Gy over 1 week

RADIATION

Historical single-dose SRS (stereotactic radiosurgery)

20 to 25Gy/1 fraction

Trial Locations (16)

14076

Centre François Baclesse, Caen

Unknown

CHU, Bordeaux

Institut Bergonié, Bordeaux

CHU, Brest

CHU, Grenoble

Centre Guillaume le Conquérant, Le Havre

Centre Oscar Lambret, Lille

Groupe hospitalier Bretagne Sud, Lorient

Centre Antoine Lacassagne, Nice

La Pitié Salpétrière, Paris

Centre hospitalier Lyon Sud, Pierre-Bénite

Centre Eugène Marquis, Rennes

Centre Henri Becquerel, Rouen

Centre d'Oncologie et Radiothérapie Saint-Jean, Saint-Doulchard

Institut Claudius Regaud, Toulouse

Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Association de Neuro-Oncologues d'Expression Francaise

OTHER

lead

Centre Francois Baclesse

OTHER